Epistem signs three-year biomarker collaboration with GlaxoSmithKline

The partnership will identify important characteristics of diseased fibrotic tissue on which Epistem will apply its proprietary RNA-Amp technology to facilitate building an in depth understanding of the disease.

RNA-Amp is an amplification technology which can provide gene expression information from small tissue samples and low of numbers of cells.

Epistem’s platform allows protein and gene expression biomarkers to be identified in important disease pathways at an early stage of pre-clinical validation for translation through to later stage clinical validation and patient stratification.